{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:49:48Z","timestamp":1790419788220,"version":"4.1.0"},"reference-count":34,"publisher":"BMJ","issue":"4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2016,2,17]]},"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:p>Botulinum toxin (BoNT) injections are an effective treatment for cervical dystonia. Approximately 20% of patients eventually stop BoNT treatment, mostly because of treatment failure. These recommendations review the different therapeutic interventions for optimising the treatment in secondary poor responder patients. Immunoresistance has become less common over the years, but the diagnosis has to be addressed with a frontalis test or an Extensor Digitorum Brevis test. In case of immunoresistance to BoNT-A, we discuss the place the different therapeutic options (BoNT-A holidays, BoNT-B injections, alternative BoNT-A injections, deep brain stimulation). When poor responders are not immunoresistant, they benefit from reviewing (1) injections technique with electromyography or ultrasound guidance, (2) muscles selection and (3) dose of BoNT. In addition, in both scenarios, a holistic approach including drug treatment, retraining and psychological support is valuable in the management of these complex and severe cervical dystonia.<\/jats:p>","DOI":"10.1136\/practneurol-2015-001335","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T22:58:52Z","timestamp":1457996332000},"page":"288-295","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor response to botulinum toxin"],"prefix":"10.1136","volume":"16","author":[{"given":"Marie-Helene","family":"Marion","sequence":"first","affiliation":[{"name":"London BTX Centre, London, UK"},{"name":"British Neurotoxin Network, Guildford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Humberstone","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nottingham University Hospitals, Nottingham, UK"},{"name":"Department of Neurology, United Lincolnshire Hospitals, Lincoln, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grunewald","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sheffield Teaching Hospitals NHS FT, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Wimalaratna","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kettering General Hospital NHS Foundation Trust, Kettering, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,3,14]]},"reference":[{"key":"2025090409565649000_16.4.288.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03042.x"},{"key":"2025090409565649000_16.4.288.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01440.x"},{"key":"2025090409565649000_16.4.288.3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.5334\/tohm.185","article-title":"Botulinum toxin therapy for cervical dystonia: the science of dosing","volume":"4","author":"Evidente","year":"2014","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"2025090409565649000_16.4.288.4","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050345"},{"key":"2025090409565649000_16.4.288.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1937"},{"key":"2025090409565649000_16.4.288.6","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s004150170028","article-title":"Efficacy and safety of a standardised 500 unit dose of Dysport (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study","volume":"248","author":"Wissel","year":"2001","journal-title":"J Neurol"},{"key":"2025090409565649000_16.4.288.7","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20022"},{"key":"2025090409565649000_16.4.288.8","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10659"},{"key":"2025090409565649000_16.4.288.9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1179\/174313209X405137","article-title":"A long-term follow-up of botulinum toxin A in cervical dystonia","volume":"31","author":"Mohammadi","year":"2009","journal-title":"Neurol Res"},{"key":"2025090409565649000_16.4.288.10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.parkreldis.2014.09.034","article-title":"Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia","volume":"21","author":"Ferreira","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"2025090409565649000_16.4.288.11","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.42.7.1307"},{"key":"2025090409565649000_16.4.288.12","first-page":"36","article-title":"The effect of total cumulative dose, number of treatment cycles, interval between injections, and length of treatment on the frequency of occurrence of antibodies to botulinum toxin type A in the treatment of muscle spasticity","volume":"35","author":"Bakheit","year":"2012","journal-title":"Int"},{"key":"2025090409565649000_16.4.288.13","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-013-0998-9"},{"key":"2025090409565649000_16.4.288.14","first-page":"725","article-title":"Profile of Xeomin\u00ae (incobotulinumtoxinA) for the treatment of blepharospasm","volume":"5","author":"Park","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"2025090409565649000_16.4.288.15","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000055087.96356.BB"},{"key":"2025090409565649000_16.4.288.16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22157"},{"key":"2025090409565649000_16.4.288.17","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-010-5880-1"},{"key":"2025090409565649000_16.4.288.18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/WNF.0b013e318263163c","article-title":"Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials","volume":"35","author":"Chinnapongse","year":"2012","journal-title":"Clin Neuropharmacol"},{"key":"2025090409565649000_16.4.288.19","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20290"},{"key":"2025090409565649000_16.4.288.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-003-1129-6"},{"key":"2025090409565649000_16.4.288.21","doi-asserted-by":"crossref","unstructured":"Hefter H , Hartmann C , Kahlen U , et al . Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins\u2014a single cohort 4-year follow-up study. BMJ Open 2012;2. doi:10.1136\/bmjopen-2011-000646","DOI":"10.1136\/bmjopen-2011-000646"},{"key":"2025090409565649000_16.4.288.22","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jns.2015.01.032","article-title":"Secondary antibody-induced treatment failure under therapy with incobotulinumtoxinA (Xeomin\u00ae) in a patient with segmental dystonia pretreated with abobotulinumtoxinA (Dysport\u00ae)","volume":"350","author":"Kamm","year":"2015","journal-title":"J Neurol Sci"},{"key":"2025090409565649000_16.4.288.23","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00702-013-1127-5","article-title":"Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis","volume":"121","author":"Hefter","year":"2014","journal-title":"J Neural Transm (Vienna)"},{"key":"2025090409565649000_16.4.288.24","first-page":"225","article-title":"Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia","volume":"27","author":"Ferreira","year":"2012","journal-title":"Funct Neurol"},{"key":"2025090409565649000_16.4.288.25","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22157"},{"key":"2025090409565649000_16.4.288.26","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21051"},{"key":"2025090409565649000_16.4.288.27","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.47.11.1166"},{"key":"2025090409565649000_16.4.288.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.4.1066"},{"key":"2025090409565649000_16.4.288.29","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1002\/mds.26009","article-title":"Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: role of M1 muscarinic receptors","volume":"29","author":"Maltese","year":"2014","journal-title":"Mov Disord"},{"key":"2025090409565649000_16.4.288.30","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.7663"},{"key":"2025090409565649000_16.4.288.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70143-7"},{"key":"2025090409565649000_16.4.288.32","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00415-013-7188-4","article-title":"Selective peripheral denervation: comparison with pallidal stimulation and literature review","volume":"261","author":"Contarino","year":"2014","journal-title":"J Neurol"},{"key":"2025090409565649000_16.4.288.33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.parkreldis.2015.04.023","article-title":"Bradykinesia induced by frequency-specific pallidal stimulation in patients with cervical and segmental dystonia","volume":"21","author":"Huebl","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"2025090409565649000_16.4.288.34","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/mds.23905","article-title":"Anterior and posterior sagittal shift in cervical dystonia: a clinical and electromyographic study, including a new EMG approach of the longus colli muscle","volume":"26","author":"Flowers","year":"2011","journal-title":"Mov Disord"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2015-001335","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T16:57:09Z","timestamp":1757005029000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2015-001335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,14]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2016,7,14]]},"published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1136\/practneurol-2015-001335"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2015-001335","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,14]]}}}